<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385281</url>
  </required_header>
  <id_info>
    <org_study_id>06-0041</org_study_id>
    <nct_id>NCT00385281</nct_id>
  </id_info>
  <brief_title>Proteomic Profiling for Influenza Vaccination - FluMist</brief_title>
  <official_title>Proteomic Profiling for Influenza Vaccination, 2nd Study: FluMist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at changes that occur in blood and nasal swab samples&#xD;
      after a person's immune system responds to receiving a flu vaccine. The investigators will&#xD;
      look at the immune response in 50 healthy volunteers, between 21 and 49 years of age, after&#xD;
      they have been vaccinated with 1 dose of a flu vaccine sprayed into the nose. A blood sample&#xD;
      and nasal swab of each nostril will be collected from volunteers before they receive the flu&#xD;
      vaccination. After receiving the flu vaccine, volunteers will record health changes and daily&#xD;
      temperatures on diary cards at home for 21 days. Blood will be drawn and nasal swabs will be&#xD;
      collected from each volunteer at each of the 6 study visits. Volunteers will participate in&#xD;
      the study for approximately 1 month. This study is being conducted at the Glennan Center for&#xD;
      Geriatrics and Gerontology at Eastern Virginia Medical School.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nonrandomized, non-comparative study conducted in 50 healthy subjects, between 21&#xD;
      and 49 years of age, who have been vaccinated with 1 dose (0.5 mL) of Influenza Virus Vaccine&#xD;
      Live, Intranasal FluMistTM, a live trivalent nasally administered vaccine. The central&#xD;
      hypothesis is that immune responses to vaccination can be quantified by proteomic profiling&#xD;
      of serum and nasal proteins, and that host responses to different infectious agents are&#xD;
      unique and can be &quot;fingerprinted&quot; by proteomics. Using influenza virus vaccination, this&#xD;
      study proposes to use mass spectrometry platforms to profile and characterize proteins from&#xD;
      serum samples obtained from recipients. These samples will be used to develop a proteomic&#xD;
      profiling system for monitoring vaccine response, and will eventually allow earlier&#xD;
      detection/diagnosis of infection. Annually, natural influenza infections cause serious&#xD;
      international public health problems that are particularly severe in elderly people, who&#xD;
      account for more than 90% of influenza mortality. The current trivalent split virus influenza&#xD;
      vaccine is cost-effective, but its efficacy is greatly reduced in the elderly population. The&#xD;
      long-term goal of the investigators' approach is to develop tools useful for reducing the&#xD;
      morbidity and mortality of influenza from natural and potential bioterrorism-related&#xD;
      infections by improving measures of vaccine efficacy and early diagnosis. This study is being&#xD;
      conducted at the Glennan Center for Geriatrics and Gerontology at Eastern Virginia Medical&#xD;
      School. Solicited adverse events (AEs) and daily temperatures will be collected on diary&#xD;
      cards for 21 days. Unsolicited AEs will also be collected throughout the duration of the&#xD;
      study. Blood will be drawn and nasal swabs will be collected from each subject at each of the&#xD;
      6 study visits. Subjects will participate in the study for approximately 1 month. The primary&#xD;
      objective of this study is to analyze serum samples before and after FluMist intranasal&#xD;
      attenuated live-virus influenza vaccination to identify surrogate markers reflective of the&#xD;
      immune response by using surface-enhanced laser desorption/ionization-time of flight&#xD;
      (SELDI-TOF) and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass&#xD;
      spectrometry proteomic profiling tools reflective of the immune response. Concurrent T-cell&#xD;
      activation, cytokine assays, and hemagglutination inhibition (HI) serologic assays will&#xD;
      correlate cellular and humoral responses to influenza vaccination with protein profiling&#xD;
      changes. Proteins obtained from intranasal swabs pre and post vaccination will be analyzed.&#xD;
      The investigators anticipate identifying multiple host response proteins from this analysis&#xD;
      using combinations of gel electrophoresis, MALDI-TOF and tandem MS/MS approaches. The&#xD;
      secondary objective is safety. Data on solicited reactions will be collected from Day 0 to&#xD;
      Day 14. The time of occurrence of AEs will be used to determine if there is a correlation&#xD;
      with the time of increase in certain protein biomarkers. The primary endpoint is to identify&#xD;
      surrogate markers reflective of the immune response in serum and/or nasal proteins and to&#xD;
      correlate these markers to cellular and humoral responses (demonstrated with T-cell&#xD;
      activation, cytokine assays, and the hemagglutination inhibition [HI] serologic assays) to&#xD;
      influenza vaccination. The secondary endpoint is safety. Data on local reactions and&#xD;
      solicited systemic reactions will be collected from Day 0 to Day 14 and categorized according&#xD;
      to severity. Unsolicited AEs will be collected and categorized throughout the study by&#xD;
      severity, duration, and relatedness to vaccine. The time of occurrence of AEs will be used to&#xD;
      determine if there is a correlation with the time of increase in certain protein biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between the ages of 21 to 49 years of age on day of enrollment, visit 1(day&#xD;
             0).&#xD;
&#xD;
          2. Provides written informed consent.&#xD;
&#xD;
          3. Subject is judged to be healthy on the basis of verbal medical and concomitant&#xD;
             medications history and has been medically stable prior to screening&#xD;
&#xD;
          4. Subject is able to attend scheduled visits and to comply with the study procedures&#xD;
             during the entire duration of the study and will be available for 1 month after&#xD;
             enrollment.&#xD;
&#xD;
          5. Female is not at risk of pregnancy, based on the following:&#xD;
&#xD;
               1. Utilizing adequate method of birth control and agree to continue using this&#xD;
                  method for at least 1 month after enrollment. Adequate methods of birth control&#xD;
                  may include hormonal (oral, transdermal, or injectable) or double barrier methods&#xD;
                  (eg condom with spermicide, vaginal combined ring) or intra-uterine device. If&#xD;
                  using hormonal method or intra-uterine device, usage should be stable for 1 month&#xD;
                  prior to vaccination and should continue for 1 month post vaccination.&#xD;
&#xD;
               2. Negative urine pregnancy test is required for all females at study entry. Females&#xD;
                  surgically sterilized (history of tubal ligation or total or subtotal&#xD;
                  hysterectomy) or post-menopausal for 2 years must still have a negative pregnancy&#xD;
                  test at time of enrollment.&#xD;
&#xD;
          6. Subject should be available through telephone contact and agree to participate in all&#xD;
             scheduled visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adults younger than 21 years of age or 50 years and older&#xD;
&#xD;
          2. Subject had physician-diagnosed (preferably by culture) influenza at any time during&#xD;
             the past 2 years.&#xD;
&#xD;
          3. Subject received an influenza vaccine in the 6 months preceding enrollment in the&#xD;
             study&#xD;
&#xD;
          4. Subjects who receive any live virus vaccine within one month of enrollment and any&#xD;
             inactivated or subunit vaccine within 2 weeks of enrollment or with plans to receive&#xD;
             any vaccine during this study will be excluded from the study, eg, pneumococcal&#xD;
             vaccine.&#xD;
&#xD;
          5. Subject received blood or blood products in the last 3 months.&#xD;
&#xD;
          6. Subject has asthma or reactive airway disease.&#xD;
&#xD;
          7. Subject has a history of any serious vaccine reactions or anaphylaxis or reactions&#xD;
             likely to be exacerbated by any component of the study vaccine,&#xD;
&#xD;
          8. Subject is allergic to eggs, egg products or gentamycin.&#xD;
&#xD;
          9. Subject has known or suspected disease(s) of the immune system with immunosuppression,&#xD;
             eg, rheumatoid arthritis, systemic lupus erythematosus (SLE), lymphoma, human&#xD;
             immunodeficiency virus (HIV), cancer diagnoses or treatment within the last 5 years&#xD;
             (except skin cancer), etc.&#xD;
&#xD;
         10. Subject is currently being treated with an immunosuppressive medications (ie, cancer&#xD;
             therapeutic agents such as tamoxifen, systemic corticosteroids such as prednisone, and&#xD;
             arthritis medications such as methotrexate). Please note that inhaled or topical&#xD;
             corticosteriods are acceptable.&#xD;
&#xD;
         11. FluMist recipients in close contact (eg, within the same household) with&#xD;
             immunocompromised individuals during periods in which the immunosuppressed person&#xD;
             requires care in a protective environment. (contact should be avoided for at least 21&#xD;
             days). Contact with small children is not an exclusion. Females who breastfeed are&#xD;
             excluded.&#xD;
&#xD;
         12. Drug interactions: On antiviral therapy in 48 hours preceding scheduled vaccination&#xD;
&#xD;
         13. Antiviral agents administered until 3 weeks after FluMist vaccination.&#xD;
&#xD;
         14. Participation in any other interventional drug or vaccine trial within 30 days prior&#xD;
             to enrollment. Therefore subject is not to receive other investigational products&#xD;
             (drug or vaccine) during the length of their participation in the trial.&#xD;
&#xD;
         15. Subject has acute respiratory illness. Administration of FluMist should be postponed&#xD;
             until after the acute phase (at least 72 hours) of respiratory illnesses.&#xD;
&#xD;
         16. Subject has active infections or illnesses.&#xD;
&#xD;
         17. Subject had an acute illness with or without fever (temperature &gt;/= 99.5 F [oral]) in&#xD;
             the 72 hours preceding vaccination. Administration of FluMist should be postponed&#xD;
             until after the acute phase (at least 72 hours) of febrile and/or acute illnesses.&#xD;
&#xD;
         18. Subject has acute or chronic medical health condition that, in the opinion of the&#xD;
             investigator, would render vaccination unsafe or would interfere with the evaluation&#xD;
             of responses. These conditions include, but are not limited to health problems&#xD;
             associated with&#xD;
&#xD;
               1. heart disease, (if heart failure is present, New York Heart Association&#xD;
                  Functional Class III or IV),&#xD;
&#xD;
               2. kidney disease, (history of significant renal impairment e.g., dialysis and&#xD;
                  treatment for kidney disease, including diabetic and hypertensive kidney&#xD;
                  disease),&#xD;
&#xD;
               3. chronic liver disorders (e.g. hepatitis B or C),&#xD;
&#xD;
               4. diabetes mellitus (excluding diet-controlled diabetes),&#xD;
&#xD;
               5. arteriosclerotic event during the 6 months prior to enrollment (eg, history of&#xD;
                  myocardial infarction, stroke, recanalization of femoral arteries, or transient&#xD;
                  ischemic attack),&#xD;
&#xD;
               6. functional or anatomic asplenia,&#xD;
&#xD;
               7. cancer diagnosed and treated within the past 5 years with chemotherapy, radiation&#xD;
                  therapy and/or surgery&#xD;
&#xD;
               8. significant anemia or other blood disorders.&#xD;
&#xD;
               9. Underlying unstable chronic disease e.g.uncontrolled hypertension (systolic blood&#xD;
                  pressure &gt;180 mm Hg or diastolic blood pressure &gt;100 mm Hg at Visit 1), etc.&#xD;
&#xD;
         19. Subject has any active neurologic disorders (ie, encephalopathy, optic&#xD;
             neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy).&#xD;
&#xD;
         20. Subject is pregnant or planning to become pregnant within the next 2 months.&#xD;
&#xD;
         21. Subject is breastfeeding.&#xD;
&#xD;
         22. Subject has any condition that would, in the opinion of the site investigator, place&#xD;
             the subject at an unacceptable risk of injury or render the subject unable to meet the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         23. Subject has a prior history of Guillain-Barr√© syndrome.&#xD;
&#xD;
         24. Subject has a history of drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <keyword>proteomic profiling, influenza, vaccine, FluMist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

